T090137 inhibits cisplatin-induced apoptosis in ovarian cancer cells

International Journal of Gynecological Cancer

Volumn 21, Issue 8, 2011, Pages 1350-1356

  Miller, Daniel H ^a   Fischer, Andrew K ^a   Chu, Katrina F ^a   Burr, Risa ^a   Hillenmeyer, Sara ^a   Brard, Laurent ^b   Brodsky, Alexander S ^a  

^a BROWN UNIVERSITY   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cisplatin; LXR; Ovarian cancer; T0901317

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; FARNESOID X RECEPTOR; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; PREGNANE X RECEPTOR; T 090137; UNCLASSIFIED DRUG; FLUORINATED HYDROCARBON; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; ORPHAN NUCLEAR RECEPTOR; SULFONAMIDE; TO-901317;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG SCREENING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; CELL CYCLE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DRUG ANTAGONISM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; ORPHAN NUCLEAR RECEPTORS; OVARIAN NEOPLASMS; SULFONAMIDES;

EID: 84863229699     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318228f558     Document Type: Article

References (28)

1. ACS Cancer Facts and Figures. 2010; Available at: http://ww2.cancer.org/ downloads/STT/Cancer-Facts-and-Figures-2010.pdf. Accessed February 8, 2011.
2. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502-516. (Pubitemid 37328838)
3. Sertznig P, Seifert M, Tilgen W, et al. Peroxisome proliferator - activated receptor (PPAR) and vitamin D receptor (VDR) signaling pathways in melanoma cells: promising new therapeutic targets? J Steroid Biochem Mol Biol. 2010;121:383-386.
4. McCullough ML, Bostick RM, Mayo TL. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr. 2009;29:111-132.
5. Peterlik M, Grant WB, Cross HS. Calcium, vitamin D and cancer. Anticancer Res. 2009;29:3687-3698.
6. Broadhead ML, Dass CR, Choong PF. Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy. Trends Mol Med. 2009;15:461-467.
7. Menendez JA. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta. 2010;1801:381-391.
8. Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator - activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther. 2009;8:6-15.
9. Ondrey F. Peroxisome proliferator - activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res. 2009;15:2-8.
10. Chuu CP, Kokontis JM, Hiipakka RA, et al. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J Biomed Sci. 2007;14:543-553. (Pubitemid 47414761)
11. Villablanca EJ, Raccosta L, Zhou D, et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med. 2010;16:98-105.
12. Scoles DR, Xu X, Wang H, et al. Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. Gynecol Oncol. 2010;116:109-116.
13. Vedin LL, Lewandowski SA, Parini P, et al. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis. 2009;30:575-579.
14. Gong H, Guo P, Zhai Y, et al. Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor. Mol Endocrinol. 2007;21:1781-1790. (Pubitemid 47173791)
15. Kim KY, Kim SS, Cheon HG. Differential anti-proliferative actions of peroxisome proliferator - activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol. 2006;72:530-540. (Pubitemid 44163294)
16. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol. 1994;72:537-545.
17. Yang C, McDonald JG, Patel A, et al. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006;281:27816-27826. (Pubitemid 44414494)
18. Mitro N, Vargas L, Romeo R, et al. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 2007;581:1721-1726. (Pubitemid 46602262)
19. Houck KA, Borchert KM, Hepler CD, et al. T0901317 is a dual LXR/FXR agonist. Mol Genet Metab. 2004;83:184-187. (Pubitemid 39311292)
20. Reed SI. Control of the G1/S transition. Cancer Surv. 1997;29:7-23.
21. Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994;79:551-555. (Pubitemid 24363798)
22. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
23. Norbury C, Blow J, Nurse P. Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J. 1991;10:3321-3329. (Pubitemid 21905357)
24. Mitsuuchi Y, Johnson SW, Selvakumaran M, et al. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res. 2000;60:5390-5394.
25. He G, Kuang J, Huang Z, et al. Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer. 2006;95:1514-1524. (Pubitemid 44863354)
26. Rough JJ, Monroy MA, Yerrum S, et al. Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res. 2010;3:13.
27. Kim KH, Lee GY, Kim JI, et al. Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity. J Lipid Res. 2010;51:3425-3433.
28. Chuu CP, Lin HP. Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Res. 2010;30:3643-3648.